Skip to main content
Premium Trial:

Request an Annual Quote

Cmbio, Nimble Science Partner for GI Multiomics Research

NEW YORK – Danish multiomics firm Cmbio said Tuesday that it has inked a partnership with Nimble Science to advance GI microbiome research.

Financial terms of the deal were not disclosed.

Cmbio will combine its multiomics data generation and analysis capabilities with Nimble's Simba GI Health Data platform to gather insights from the small intestine.

Nimble's platform utilizes the Simba Capsule, a noninvasive ingestible device that can collect luminal fluid in the small intestine.

Cmbio said the collaboration will provide clients with biological insights such as identifying microbiota-driven mechanisms that impact nutrient absorption, immune modulation, and metabolic pathways, paving the way for targeted therapies and precision interventions.

"By incorporating Nimble's innovative data platform into our multiomics services, we can now offer our clients access to previously unreachable data from the small intestine," Cmbio CEO Anders Grøn said in a statement. "This will enable deeper scientific discoveries and accelerate the development of innovative microbiome-based solutions."

Founded in November through the merger of several companies, Cmbio also acquired the software assets of Eagle Genomics, a UK-based bioinformatics tool developer, earlier this month.